Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of cysteamine in patients with
symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo)
on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study
group 1996).